Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
ASH 2016 - Chronic Lymphocytic Leukemia
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Salvage Use of Ibrutinib After allo-HSCT for B-Cell Malignancies: A Study of the French Cooperative Group for CLL, the French Society for Blood and Marrow Transplantation (SFGM-TC), and the EBMT Chronic Malignancy and Lymphoma Working Parties
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
CLL2-BIG – A Novel Treatment Regimen of Bendamustine Followed by GA101 and Ibrutinib Followed by Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase 2 Trial
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multicenter Study of 683 US Patients
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Comparing Healthcare Utilization of 2 Drug Regimens in Patients with CLL
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft-versus-Host Disease (cGVHD) After Failure of Corticosteroids
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Reviewing the Demographics and First-Line Treatment Patterns in Patients with CLL
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Phase 1b Results of a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Changes in Clinical Stage Identify Different Response Categories Among Patients in iwCLL PR: Analysis of CLL Patients on the RESONATE Study
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter’s Transformation: An Updated Report from a Phase 2 Trial (MC1485)
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Read More
1
2
Page 1 of 2
Results 1 - 10 of 20
